Histone deacetylase 1, 2, 3, 6, and 8 (HDAC1/2/3/6/8)

Histone deacetylases (HDACs) 1, 2, 3, 6, and 8 are a group of zinc-dependent enzymes that play a pivotal role in epigenetic regulation by removing acetyl groups from lysine residues on histones and various non-histone proteins (MedChemExpress; NIH). HDAC1, 2, 3, and 8 belong to Class I and are primarily nuclear, while HDAC6 is a Class IIb enzyme predominantly located in the cytoplasm where it targets substrates like alpha-tubulin and Hsp90 (NIH; MDPI). By promoting chromatin condensation, these enzymes typically act as transcriptional repressors, and their dysregulation is frequently linked to the silencing of tumor suppressor genes and the promotion of oncogenic pathways (Oxford University Press; NIH). Consequently, they have become major therapeutic targets in oncology, with several FDA-approved inhibitors like vorinostat and panobinostat used to treat hematological malignancies (NIH). Beyond cancer, these HDAC isoforms are also implicated in neurodegenerative and inflammatory diseases, making them versatile targets for drug development (NIH). However, the use of multi-HDAC inhibitors is often limited by systemic toxicities, such as myelosuppression and cardiotoxicity, driving research toward more isoform-selective agents (NIH).

Other names

Class I and IIb histone deacetylasesZinc-dependent histone deacetylasesKDAC1/2/3/6/8Classical histone deacetylases (subset)

Inhibition of the catalytic activity of HDAC enzymes, leading to hyperacetylation of histones and non-histone proteins, which promotes an open chromatin state and modulates the transcription of genes involved in cell growth and survival.